ATDC induces an invasive switch in KRAS-induced pancreatic tumorigenesis

Genes and Development

Volumn 29, Issue 2, 2015, Pages 171-183

  Wang, Lidong ^a   Yang, Huibin ^a   Abel, Ethan V ^a   Ney, Gina M ^a,b   Palmbos, Phillip L ^a,b   Bedna, Filip ^a   Zhang, Yaqing ^a   Leflein, Jacob ^a   Waghray, Meghna ^a   Owens, Scott ^b   Wilkinson, John E ^b   Prasad, Jayendra ^a,b   Ljungman, Mats ^a,b   Rhim, Andrew D ^b   Di Magliano, Marina Pasca ^a,b   Simeone, Diane M ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Epithelial mesenchymal transition; Metastasis; Pancreatic ductal adenocarcinoma

Indexed keywords

BETA CATENIN; HERMES ANTIGEN; K RAS PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL1; TRANSCRIPTION FACTOR ZEB1; TRIPARTITE MOTIF PROTEIN 29; TUMOR MARKER; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; KRAS2 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; PROTEIN P21; SNAIL FAMILY TRANSCRIPTION FACTORS; TRIM29 PROTEIN, MOUSE; ZEB1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; METASTASIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREATIC CARCINOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA; TUMOR INVASION; UPREGULATION; ANIMAL; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOPHYSIOLOGY; PROMOTER REGION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD44; BETA CATENIN; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); TRANSCRIPTION FACTORS;

EID: 84921495264     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.253591.114     Document Type: Article

References (36)

1. Afify A, Purnell P, Nguyen L. 2009. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 86: 95–100.
2. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112–3126.
3. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. 2009. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820–5828.
4. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H. 2010. SLUG/SNAI2 and tumor necrosis factor generate breast cells with D44+/CD24_ phenotype. BMC Cancer 10: 411.
5. Biankin AV, Waddell N, Kassahn KS, Gingras M C, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491: 399–405.
6. Blauwkamp TA, Chang MV, Cadigan KM. 2008. Novel TCFbinding sites specify transcriptional repression by Wnt signalling. EMBO J 27: 1436–1446.
7. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C. 2011. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial–mesenchymal transition and breast cancer progression. J Clin Invest 121: 1064–1074.
8. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD. 2007. Loss of homotypic cell adhesion by epithelial–mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6: 532–541.
9. Craig EA, Parker P, Camenisch TD. 2009. Size-dependent regulation of Snail2 by hyaluronan: its role in cellular invasion. Glycobiology 19: 890–898.
10. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. 2006. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218–1249.
11. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437–450.
12. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469–483.
13. Hotz B, Arndt M, Dullat S, Bhargava S, Buhr HJ, Hotz HG. 2007. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 13: 4769–4776.
14. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, et al. 2001. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 25: 579–586.
15. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. 2002. Wnt/b-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22: 1172–1183.
16. Jung T, Gross W, Zoller M. 2011. CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 286: 15862–15874.
17. Kanegae Y, Lee G, Sato Y, Tanaka M, Nakai M, Sakaki T, Sugano S, Saito I. 1995. Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res 23: 3816–3821.
18. Kim Y, Lee YS, Choe J, Lee H, Kim YM, Jeoung D. 2008. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283: 22513–22528.
19. Li L, Hao X, Qin J, Tang W, He F, Smith A, Zhang M, Simeone DM, Qiao XT, Chen ZN, et al. 2014. Antibody against CD44s inhibits pancreatic tumor initiation and post-radiation recurrence in mice. Gastroenterology 146: 1108–1118.
20. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, Misek DE, Kuick R, Hanash S. 2003. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 63: 2649–2657.
21. Malumbres M, Barbacid M. 2003. RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459–465.
22. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, et al. 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200–1210.
23. Nisole S, Stoye JP, Saib A. 2005. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 3: 799–808.
24. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 2012. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418–429.
25. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. 2014. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74: 2913–2921.
26. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, et al. 2012. EMT and dissemination precede pancreatic tumor formation. Cell 148: 349–361.
27. Sakorafas GH, Sarr MG. 2003. Pancreatic cancer after surgery for chronic pancreatitis. Dig Liver Dis 35: 482–485.
28. Sanchez-Tillo E, de Barrios O, Siles L, Cuatrecasas M, Castells A, Postigo A. 2011. b-Catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci 108: 19204–19209.
29. Tuveson DA, Neoptolemos JP. 2012. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148: 21–23.
30. Valastyan S, Weinberg RA. 2011. Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275–292.
31. Vogelstein B, Kinzler KW. 2004. Cancer genes and the pathways they control. Nat Med 10: 789–799.
32. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. 2013. Cancer genome landscapes. Science 339: 1546–1558.
33. Wang L, Heidt DG, Lee CJ, Yang H, Logsdon CD, Zhang L, Fearon ER, Ljungman M, Simeone DM. 2009. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and b-catenin stabilization. Cancer Cell 15: 207–219.
34. Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, Clevers H, Pals ST. 1999. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515–523.
35. Wolf D, Goff SP. 2007. TRIM28 mediates primer binding sitetargeted silencing of murine leukemia virus in embryonic cells. Cell 131: 46–57.
36. Yuan Z, Villagra A, Peng L, Coppola D, Glozak M, Sotomayor EM, Chen J, Lane WS, Seto E. 2010. The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions. Mol Cell Biol 30: 3004–3015.